RELMADA THERAPEUTICS, INC. Income (Loss) from Equity Method Investments
RELMADA THERAPEUTICS, INC. (RLMD) reported Income (Loss) from Equity Method Investments of -$666.71 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2023-08-08
- RELMADA THERAPEUTICS, INC. income (loss) from equity method investments for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. income (loss) from equity method investments for the quarter ending 2023-03-31 was -$666.71K.
- RELMADA THERAPEUTICS, INC. income (loss) from equity method investments for the quarter ending 2022-12-31 was -$33.35K.
- RELMADA THERAPEUTICS, INC. income (loss) from equity method investments for the quarter ending 2022-09-30 was -$561.65K.
- RELMADA THERAPEUTICS, INC. income (loss) from equity method investments for fiscal 2022 was -$585.52K.
- RELMADA THERAPEUTICS, INC. income (loss) from equity method investments for fiscal 2021 was -$636.01K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$666.71K 10-Q · filed 2023-08-08 | -$700.06K derived: sum of 3 quarters · filed 2023-08-08 | -$1.26M derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | -$666.71K 10-Q · filed 2023-05-11 | -$700.06K derived: sum of 2 quarters · filed 2023-05-11 | -$1.26M derived: sum of 3 quarters · filed 2023-05-11 | -$1.24M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-12-31 | -$33.35K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$595.00K derived: sum of 2 quarters · filed 2023-03-23 | -$570.50K derived: sum of 3 quarters · filed 2023-08-08 | -$585.52K 10-K · filed 2023-03-23 |
| 2022-09-30 | -$561.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$537.15K derived: sum of 2 quarters · filed 2023-08-08 | -$552.17K 10-Q · filed 2022-11-10 | -$674.86K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-06-30 | $24.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.48K 10-Q · filed 2023-08-08 | -$113.20K derived: sum of 3 quarters · filed 2023-08-08 | -$450.15K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$15.02K 10-Q · filed 2023-05-11 | -$137.71K derived: sum of 2 quarters · filed 2023-05-11 | -$474.65K derived: sum of 3 quarters · filed 2023-05-11 | -$598.25K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$122.68K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$459.63K derived: sum of 2 quarters · filed 2023-03-23 | -$583.22K derived: sum of 3 quarters · filed 2023-03-23 | -$636.01K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$336.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$460.54K derived: sum of 2 quarters · filed 2022-11-10 | -$513.33K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$123.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$176.38K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$52.79K 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | -$244.97K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |